Kimberly L. Blackwell, MD
The HER2-positive breast cancer space has seen a wave of novel treatments and FDA approvals.
, Blackwell, a medical oncologist at Duke Cancer Institute, discussed these novel agents and other recent advancements in the treatment paradigm of HER2-positive breast cancer.
OncLive: What are your thoughts on the data reported with tucatinib in patients with brain metastases?
: Tucatinib is one of the most exciting agents out there in the investigative space that is trying to improve on current therapies for HER2-positive breast cancer. The data out of the 2017 San Antonio Breast Cancer Symposium evaluated giving tucatinib, a small molecule inhibitor very specific against HER2, prior to a patient receiving whole-brain radiotherapy in patients who are facing brain metastases.
... to read the full story